

Maria Bieniaszewska

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5126149/publications.pdf>

Version: 2024-02-01

18
papers

190
citations

1478505

6
h-index

1281871

11
g-index

19
all docs

19
docs citations

19
times ranked

351
citing authors

#	ARTICLE	IF	CITATIONS
1	Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial. <i>Lancet Haematology</i> , 2020, 7, e28-e39.	4.6	94
2	Colonization with multidrug-resistant bacteria increases the risk of complications and a fatal outcome after allogeneic hematopoietic cell transplantation. <i>Annals of Hematology</i> , 2018, 97, 509-517.	1.8	31
3	Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial. <i>American Journal of Hematology</i> , 2022, 97, 1023-1034.	4.1	17
4	Relationships between thrombohemorrhagic complications and platelet function in patients with essential thrombocythaemia. <i>American Journal of Hematology</i> , 2001, 68, 32-36.	4.1	12
5	Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs. <i>Blood Advances</i> , 2022, 6, 5171-5183.	5.2	12
6	Association of cytokine gene polymorphisms with the complications of allogeneic haematopoietic stem cell transplantation. <i>Human Immunology</i> , 2017, 78, 672-683.	2.4	10
7	Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q). <i>BMC Cancer</i> , 2015, 15, 508.	2.6	5
8	Immune Status Against Hepatitis B in Patients After Allogeneic Hematopoietic Cell Transplantation – Factors Affecting Early and Long-Lasting Maintenance of Protective Anti-HBs Titers. <i>Frontiers in Immunology</i> , 2020, 11, 586523.	4.8	4
9	Late polycythemic transformation in JAK2 mutated essential thrombocythemia patients – characteristics along with a validation of 2016 WHO criteria. <i>European Journal of Haematology</i> , 2019, 103, 558-563.	2.2	2
10	Clinical characteristics of essential thrombocythemia patients depend on the mutation status. <i>Acta Haematologica Polonica</i> , 2020, 51, 230-235.	0.3	2
11	The molecular analysis of four coexistent mutations in additional sex combs like 1 (ASXL1) gene in a patient with acute myeloid leukemia. <i>Journal of Hematopathology</i> , 2020, 13, 165-168.	0.4	1
12	Significance of Minimal Residual Disease in Patients with Chronic Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2009, 114, 3269-3269.	1.4	0
13	Role of Second Stem Cell Transplantation in Relapsed Lymphoproliferative Diseases: Remission Status Is the Most Important Factor Predicting the Outcome. <i>Blood</i> , 2011, 118, 3109-3109.	1.4	0
14	Analysis of Predictive Factors for Early Response to Ruxolitinib in 266 Patients with Myelofibrosis from the Polish Adult Leukemia Group (PALG) Registry. <i>Blood</i> , 2019, 134, 4180-4180.	1.4	0
15	Antifungal management in adults and children with hematological malignancies or undergoing hematopoietic cell transplantation: recommendations of Polish Society of Hematology and Blood Transfusion, Polish Society of Pediatric Oncology and Hematology, and Polish Adult Leukemia Study Group. 2020. <i>Acta Haematologica Polonica</i> . 2020. 51, 60-72.	0.3	0
16	The beneficial role of allogeneic hematopoietic cell transplantation in blastic plasmacytoid dendritic cell neoplasm. <i>Acta Haematologica Polonica</i> , 2020, 51, 236-244.	0.3	0
17	The Prognostic Value of Early Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Treated with Intensive Chemotherapy - Preliminary Results of Polish Adult Leukemia Group PALG-AML1/2016 Study. <i>Blood</i> , 2021, 138, 3453-3453.	1.4	0
18	Secondary chronic myeloid leukemia in a patient with CALR and ASXL1-mutated primary myelofibrosis. <i>International Journal of Hematology</i> , 2022, , 1.	1.6	0